-
公开(公告)号:US20170240511A1
公开(公告)日:2017-08-24
申请号:US15517553
申请日:2015-10-08
申请人: Fez UJJAINWALLA , John Qiang TAN , Qun DANG , Christopher J. SINZ , Ming WANG , Jiaqiang CAI , Xiaoxing DU , Yili CHEN , MERCK SHARP & DOHME CORP.
发明人: FEZ UJJAINWALLA , JOHN QIANG TAN , QUN DANG , CHRISTOPHER J. SINZ , MING WANG , JIAQIANG CAI , XIAOXING DU , YILI CHEN
IPC分类号: C07D213/82 , C07D401/04
CPC分类号: C07D213/82 , A61P7/08 , C07D401/04
摘要: The present invention concerns compounds of formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
-
公开(公告)号:US20170240513A1
公开(公告)日:2017-08-24
申请号:US15517550
申请日:2015-10-08
申请人: FEZ UJJAINWALLA , JOHN QIANG TAN , QUN DANG , CHRISTOPHER J. SINZ , MING WANG , YILI CHEN , JIAQIANG CAI , MERCK SHARP & DOHME CORP.
发明人: FEZ UJJAINWALLA , JOHN QIANG TAN , QUN DANG , CHRISTOPHER J. SINZ , MING WANG , YILI CHEN , JIAQIANG CAI
IPC分类号: C07D239/36 , C07D413/06
CPC分类号: C07D239/36 , A61P7/06 , C07D413/06
摘要: The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
-
公开(公告)号:US20170247336A1
公开(公告)日:2017-08-31
申请号:US15517557
申请日:2015-10-08
发明人: FEZ UJJAINWALLA , JOHN QIANG TAN , QUN DANG , CHRISTOPHER J. SINZ , ALEJANDRO CRESPO , MING WANG , YILI CHEN , JIAQIANG CAI , FAN WU , XIAOXING DU
IPC分类号: C07D239/36 , C07D401/12 , C07D405/12 , C07D403/12
CPC分类号: C07D239/36 , C07D239/34 , C07D401/12 , C07D403/12 , C07D405/12
摘要: The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
-
-